Drug-resistant Tuberculosis Treatment Market Analysis

Treatment (First-Line Anti-TB Drugs, Second-Line Anti-TB Drugs)

First-line anti-TB drugs segment is projected to dominate drug-resistant tuberculosis treatment market share of around 60% by the end of 2036.  The segment growth is attributed to FDA approval of medicines, as the developed drug is very effective, and the non-toxic nature of the drug for the treatment of Mycobacterium tuberculosis infections. For new patients, isoniazid, rifampin, pyrazinamide, and one of these - ethambutol or streptomycin, are used. Moreover, these drugs are very effective and can be used with multiple other antibiotics for the treatment of tuberculosis. Moreover, the researchers are focusing on vaccines as this disease is epidemic in some countries.

According to the U.S. Centers for Disease Control and Prevention report 2023, there are particularly 2 types of regimens for tuberculosis treatment - 4-month Rifapentine-moxifloxacin and 6- or 9-month. Further, 4-month Rifapentine moxifloxacin helps in fastening the treatment so that patients may recover early and healthcare staff can look after other patients.

Disease (Active TB, Latent TB)

In drug-resistant tuberculosis treatment market, active TB segment is likely to capture revenue share of over 40% by 2036. Active TB is very harmful since it spreads from one person to another often via air. Moreover, active TB simply means that the germs are growing and impairing tissues present inside the body.

Further, a person is firstly infected by latent TB (primary infection) and afterward by active TB. This happens when the immune system is not resistant to infections. According to a recent report issued in 2022, around 25% of world’s population is infected with TB, out of which 5.8 million were men and 3.5 million women.  

Distribution Channel (Hospital, Online Pharmacies, Retail Pharmacies)

By the end of 2036, hospital pharmacies segment is expected to hold drug-resistant tuberculosis treatment market share of over 42%. The segment growth is attributed to instant access to specialized medicines. Both inpatients, outpatients, and in some emergency, cases can easily access these medicines. As per the recent data issued in 2024, there are 685 exporters and 1159 buyers of TB medicines across the world.

Our in-depth analysis of the global market includes the following segments: